Lilly’s COVID-19 antibody treatment authorized for young children and infants


Shares of Eli Lilly & Co. LLY, -0.93% were down 1.6% in trading on Friday after the company said the Food and Drug Administration has extended the emergency authorization for its COVID-19 antibody therapy to include children younger than 12 years old. This is the first authorization for a monoclonal antibody treatment for infants and children. Lilly said the therapy can now be used in high-risk children as a treatment or for post-exposure prophylaxis. The company also said that more than 700,000 patients have been treated with bamlanivimab or a combination of bamlanivimab and etesevimab. Lilly’s stock is up 44.5% so far this year, while the broader S&P 500 SPX, -0.84% has gained 21.6%.

This article was originally published by Read the original article here.

Previous article: Adobe worth $26 billion less as DocuSign fears spark ‘knee-jerk reaction’ for stock
Next articleWHO says it has seen no reports of omicron deaths and cautions against panic


Please enter your comment!
Please enter your name here